Guilin Sanjin Pharmaceutical Co Ltd Financial Flexibility Index
Guilin Sanjin Pharmaceutical Co Ltd financial flexibility index. Guilin Sanjin Pharmaceutical Co Ltd (002275) has a Financial Flexibility Index of 0.23x as of September 2025. Free cash flow of CN¥241.88 Million (operating CF CN¥117.62 Million minus capex CN¥124.26 Million) represents 0% of total liabilities (CN¥1.05 Billion). Explore 002275 capital reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of Guilin Sanjin Pharmaceutical Co Ltd (2006–2024)
Financial flexibility index of Guilin Sanjin Pharmaceutical Co Ltd from 2006 to 2024. Historical Financial Flexibility Index trend for Guilin Sanjin Pharmaceutical Co Ltd across 19 annual periods. Check 002275 total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Guilin Sanjin Pharmaceutical Co Ltd Financial Flexibility Index by Year (2006–2024)
Guilin Sanjin Pharmaceutical Co Ltd financial flexibility index by year from 2006 to 2024. Year-by-year free cash flow to debt coverage for Guilin Sanjin Pharmaceutical Co Ltd. For the full cash flow conversion analysis, see cash flow conversion of Guilin Sanjin Pharmaceutical Co Ltd.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.55x | CN¥670.51 Million | CN¥588.33 Million | CN¥1.22 Billion | ▼ -1.9% |
| 2023 | 0.56x | CN¥625.64 Million | CN¥549.25 Million | CN¥1.12 Billion | ▲ +8.9% |
| 2022 | 0.51x | CN¥590.93 Million | CN¥528.67 Million | CN¥1.15 Billion | ▲ +16.3% |
| 2021 | 0.44x | CN¥554.33 Million | CN¥410.24 Million | CN¥1.26 Billion | ▼ -49.3% |
| 2020 | 0.87x | CN¥803.46 Million | CN¥597.99 Million | CN¥923.27 Million | ▼ -24.8% |
| 2019 | 1.16x | CN¥694.43 Million | CN¥468.29 Million | CN¥600.18 Million | ▲ +8.1% |
| 2018 | 1.07x | CN¥641.69 Million | CN¥551.73 Million | CN¥599.47 Million | ▲ +37.1% |
| 2017 | 0.78x | CN¥449.35 Million | CN¥387.82 Million | CN¥575.65 Million | ▼ -42.4% |
| 2016 | 1.36x | CN¥602.21 Million | CN¥536.85 Million | CN¥444.26 Million | ▲ +7.9% |
| 2015 | 1.26x | CN¥523.51 Million | CN¥398.50 Million | CN¥416.59 Million | ▼ -4.3% |
| 2014 | 1.31x | CN¥607.81 Million | CN¥396.53 Million | CN¥463.07 Million | ▲ +1.8% |
| 2013 | 1.29x | CN¥627.00 Million | CN¥314.16 Million | CN¥486.11 Million | ▲ +3.4% |
| 2012 | 1.25x | CN¥508.22 Million | CN¥302.59 Million | CN¥407.26 Million | ▼ -41.8% |
| 2011 | 2.14x | CN¥467.80 Million | CN¥341.05 Million | CN¥218.18 Million | ▲ +1.3% |
| 2010 | 2.12x | CN¥383.93 Million | CN¥285.49 Million | CN¥181.47 Million | ▲ +41.2% |
| 2009 | 1.50x | CN¥417.97 Million | CN¥363.29 Million | CN¥279.00 Million | ▲ +147.1% |
| 2008 | 0.61x | CN¥229.61 Million | CN¥190.97 Million | CN¥378.65 Million | ▲ +16.5% |
| 2007 | 0.52x | CN¥181.98 Million | CN¥164.39 Million | CN¥349.58 Million | ▼ -56.9% |
| 2006 | 1.21x | CN¥246.82 Million | CN¥217.67 Million | CN¥204.48 Million | — |